Early diagnosis value of NLR,PCT and CRP combined determination for COVID-19

doi:10.3969/j.issn.1673-8640.2021.01.011

Abstract

Abstract:

Objective To investigate the value of neutrophil/lymphocyte ratio（NLR）,procalcitonin（PCT） and C-reactive protein（CRP） determinations in the early diagnosis of corona virus disease 2019（COVID-19）. Methods A total of 230 suspected COVID-19 patients were enrolled and classified into COVID-19 group（80 cases）,cold group（100 cases） and bacterial group（50 cases）according to thorax computed tomography（CT）,severe acute respiratory syndrome coronavirus 2（SARS-CoV-2） nucleic acid,viral serological antibody and blood culture results. The levels of white blood cell（WBC） count,the absolute value of neutrophil（NEUT#）,the absolute value of lymphocyte（LYMPH#）,the percentage of lymphocyte（LYMPH%）,the absolute value of easinosphils（EO#）,NLR,PCT and CRP among the 3 groups were compared. Results Compared with cold group,COVID-19 group had higher levels of NLR and CRP,and the levels of LYMPH%,LYMPH# and EO# were lower（P<0.05）. Compared with bacterial group,COVID-19 group had lower levels of LYMPH#,EO#,NEUT#,PCT and WBC count（P<0.05）. Compared with cold group,COVID-19 group had higher proportions of WBC count<4.00,LYMPH#<0.80,LYMPH%<20%,EO#<0.05,NLR>3.0 and CRP≥10.00（P<0.05）. Compared with bacterial group,COVID-19 group had higher proportions of WBC count<4.00,NEUT#<2.00,LYMPH#<0.80 and EO#<0.05（P<0.05）and lower proportions of WBC count>10.00,NEUT#>7.00,EO#>0.50,PCT≥0.50（P<0.05）. Conclusions Decreased LYMPH#,normal PCT and increased NLR and CRP are early markers of COVID-19 patients. The combined determination can be used as a supplement to SARS-CoV-2 nucleic acid determination.

Key words: Corona virus disease 2019, Absolute value of lymphocyte, Neutrophil/lymphocyte ratio, Procalcitonin, C-reactive protein

CLC Number:

R446.1

ZHU Chuanxin, ZHOU Yuping, ZHOU Qin, ZHOU Guifeng. Early diagnosis value of NLR,PCT and CRP combined determination for COVID-19[J]. Laboratory Medicine, 2021, 36(1): 53-56.

Figures/Tables 2

References 13

[1]	ZHAO Z,XIE J,YIN M,et al. Clinical and laboratory profiles of 75 hospitalized patients with novel coronavirus disease 2019 in Hefei,China[J/OL]. medRxiv,.
[2]	李园园,王伟娜,雷宇,等. 临床诊断新型冠状病毒肺炎中核酸检测阳性与阴性患者临床特征的比较[J]. 中华结核和呼吸杂志,2020,43(5):427-430.
[3]	鲁彦,居军,李德红. 核酸和血清学指标结合,多类型标本联检,提高新型冠状病毒检出率[J]. 检验医学与临床,2020,17(9):1161-1163.
[4]	国家卫生健康委办公厅. 新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL]. (2020-02-18)[2020-02-20]. .
[5]	范久波,孙莉,何家富,等. SAA联合CRP、血常规检测在新型冠状病毒肺炎中的诊断价值[J]. 检验医学,2020,35(7):640-644.
[6]	HUANG C,WANG Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet,2020,395(10223):497-506.
[7]	复旦大学附属中山医院新型冠状肺炎诊治专家组,宋元林. 复旦大学附属中山医院新型冠状病毒肺炎疑似病例诊治方案(2020 v.1)[J]. 中国临床医学,2020,27(1):13-15.
[8]	颜宇飞,金一鸣,刘明利,等. NLR在SARS-CoV-2感染中的临床意义探讨[J]. 检验医学,2020,35(7):637-639.
[9]	于恪,黄河,邓海燕,等. 淋巴细胞计数对新型冠状病毒肺炎的诊断价值[J]. 广东医学,2020,41(8):776-780.
[10]	王春娟,雷刚平,刘俊娜,等. PCT、CRP、IL-6联合检测对细菌性血流感染的早期诊断价值[J]. 国际检验医学杂志,2019,40(13):1600-1602.
[11]	吴琼,李丽娟,刘国梁,等. 中性粒细胞/淋巴细胞比值联合降钙素原检测在血流感染诊断中的价值[J]. 检验医学,2016 ,31(10):898-901.
[12]	陈星,区静怡,黄颖,等. 多种血液学指标在新型冠状病毒肺炎中的诊断价值[J]. 检验医学,2020,35(4):295-299.
[13]	CHEN X P,LING J X,MO Z,et al. Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients[EB/OL]. medRxiv,.

组别	例数	WBC计数/（×10⁹/L）	NEUT#/（×10⁹/L）	LYMPH#/（×10⁹/L）	LYMPH%/%
COVID-19组	80	4.88（3.64,6.11）	3.16（2.15,4.42）	1.07（0.89,1.46）	19.00（13.50,26.80）
感冒组	100	5.12（4.95,7.50）	3.25（2.55,4.30）	2.51（2.05,3.94）	35.0（29.50,40.80）
细菌组	50	11.65（10.02,13.50）	9.85（8.02,13.00）	1.85（1.39,2.90）	18.70（15.50,25.80）
T值		47.68	35.22	7.89	6.34
P值		0.000	0.001	0.001	0.002
组别		EO#/（×10⁹/L）	NLR	CRP/（mg/L）	PCT/（ng/mL）
COVID-19组		0.03（0.01,0.05）	3.55（2.61,4.70）	20.55（18.20,34.90）	0.22（0.19,0.38）
感冒组		0.07（0.06,0.10）	1.25（0.81,1.70）	6.50（4.50,10.20）	0.18（0.14,0.31）
细菌组		0.06（0.05,0.09）	4.85（3.05,6.30）	26.80（19.50,36.00）	2.78（1.50,3.95）
T值		8.80	3.41	21.42	41.01
P值		0.002	0.010	0.002	0.001

组别	例数	WBC计数/（×10⁹/L）	NEUT#/（×10⁹/L）	LYMPH#/（×10⁹/L）	LYMPH%/%
COVID-19组	80	4.88（3.64,6.11）	3.16（2.15,4.42）	1.07（0.89,1.46）	19.00（13.50,26.80）
感冒组	100	5.12（4.95,7.50）	3.25（2.55,4.30）	2.51（2.05,3.94）	35.0（29.50,40.80）
细菌组	50	11.65（10.02,13.50）	9.85（8.02,13.00）	1.85（1.39,2.90）	18.70（15.50,25.80）
T值		47.68	35.22	7.89	6.34
P值		0.000	0.001	0.001	0.002
组别		EO#/（×10⁹/L）	NLR	CRP/（mg/L）	PCT/（ng/mL）
COVID-19组		0.03（0.01,0.05）	3.55（2.61,4.70）	20.55（18.20,34.90）	0.22（0.19,0.38）
感冒组		0.07（0.06,0.10）	1.25（0.81,1.70）	6.50（4.50,10.20）	0.18（0.14,0.31）
细菌组		0.06（0.05,0.09）	4.85（3.05,6.30）	26.80（19.50,36.00）	2.78（1.50,3.95）
T值		8.80	3.41	21.42	41.01
P值		0.002	0.010	0.002	0.001

组别	例数	WBC计数/（×10⁹/L）			NEUT#/（×10⁹/L）
组别	例数	<4.00	4.00~10.00	>10.00	<2.00		2.00~7.00		>7.00
COVID-19组	80	23.75	76.15	0	12.50		87.50		0
感冒组	100	14.00	83.00	3.00	9.00		88.00		3.00
细菌组	50	0	18.00	82.00	0		10.00		90.00
T值		55.67	10.24	5.11	4.73		3.27		-1.02
P值		0.028	0.001	0.000	0.000		0.000		0.000
组别	LYMPH#/（×10⁹/L）			LYMPH%/%					CRP/（mg/L）
组别	<0.80	0.80~4.00	>4.00	<20.00		20.00~40.00		>40.00	≥10.00	<10.00
COVID-19组	26.25	72.50	1.25	33.75		65.00		1.25	56.25	43.75
感冒组	0	52.00	48.00	0		44.00		56.00	4.00	96.00
细菌组	0	96.00	4.00	26.00		70.00		4.00	80.00	20.00
T值	0.61	7.67	1.02	0.44		34.57		2.33	12.36	9.28
P值	0.000	0.081	0.000	0.000		0.004		0.000	0.001	0.002
组别	EO#/（×10⁹/L）			NLR					PCT/（ng/mL）
组别	<0.05	0.05~0.50	>0.50	<1.50		1.50~3.00		>3.00	<0.50	≥0.50
COVID-19组	36.25	62.50	1.25	0		48.75		51.25	98.75	1.25
感冒组	9.00	79.00	12.00	48.00		50.0		2.00	97.00	3.00
细菌组	8.00	72.00	20.00	0		30.00		70.00	4.00	96.00
T值	15.64	2.20	2.69	-2.11		4.55		41.00	32.56	61.00
P值	0.001	0.611	0.047	0.000		0.159		0.000	0.000	0.000

组别	例数	WBC计数/（×10⁹/L）			NEUT#/（×10⁹/L）
组别	例数	<4.00	4.00~10.00	>10.00	<2.00		2.00~7.00		>7.00
COVID-19组	80	23.75	76.15	0	12.50		87.50		0
感冒组	100	14.00	83.00	3.00	9.00		88.00		3.00
细菌组	50	0	18.00	82.00	0		10.00		90.00
T值		55.67	10.24	5.11	4.73		3.27		-1.02
P值		0.028	0.001	0.000	0.000		0.000		0.000
组别	LYMPH#/（×10⁹/L）			LYMPH%/%					CRP/（mg/L）
组别	<0.80	0.80~4.00	>4.00	<20.00		20.00~40.00		>40.00	≥10.00	<10.00
COVID-19组	26.25	72.50	1.25	33.75		65.00		1.25	56.25	43.75
感冒组	0	52.00	48.00	0		44.00		56.00	4.00	96.00
细菌组	0	96.00	4.00	26.00		70.00		4.00	80.00	20.00
T值	0.61	7.67	1.02	0.44		34.57		2.33	12.36	9.28
P值	0.000	0.081	0.000	0.000		0.004		0.000	0.001	0.002
组别	EO#/（×10⁹/L）			NLR					PCT/（ng/mL）
组别	<0.05	0.05~0.50	>0.50	<1.50		1.50~3.00		>3.00	<0.50	≥0.50
COVID-19组	36.25	62.50	1.25	0		48.75		51.25	98.75	1.25
感冒组	9.00	79.00	12.00	48.00		50.0		2.00	97.00	3.00
细菌组	8.00	72.00	20.00	0		30.00		70.00	4.00	96.00
T值	15.64	2.20	2.69	-2.11		4.55		41.00	32.56	61.00
P值	0.001	0.611	0.047	0.000		0.159		0.000	0.000	0.000

[1]	LI Li, SUN Haiyan, LI Yuanrui, DOU Min, TANG Wen, JIANG Limin, SHEN Lisong. Changes and clinical roles of perioperative NT-proBNP and PCT in children with congenital heart disease [J]. Laboratory Medicine, 2023, 38(6): 524-531.
[2]	WU Caorong, CUI Wen, TANG Binbin, HE Jingjing, LAI Zhikun. Correlations between the ratio of C-reactive protein to prealbumin and the prognosis of patients with acute heart failure [J]. Laboratory Medicine, 2023, 38(6): 579-583.
[3]	DENG Xu, ZHUANG Wenlong, XUE Hui, ZHU Shuqin, LI Ying. Relationship between neutrophil/lymphocyte ratio，fibrinogen and carotid intima-media thickness in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(4): 368-372.
[4]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[5]	YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93.
[6]	ZHAI Shana, SUN Qinghai, YU Yongwu, YE Fang, LIU Maodong. Influence of vancomycin combined with meropenem on serum TNF-α,PCT,IL-6 and peritoneal fluid WBC count in PDRP patients [J]. Laboratory Medicine, 2022, 37(4): 360-364.
[7]	LI Dongxiu, HUANG Jian. Roles of serum sICAM-1 and hs-CRP levels in monitoring acute viral lower respiratory tract infection in children [J]. Laboratory Medicine, 2022, 37(3): 226-229.
[8]	SONG Yunxiao, TONG Wei, ZHANG Haichen, ZHANG Yinwang, BIAN Xiaobo, ZHANG Linlin, YUAN Wenhua, ZHAO Zhiyun, GE Wen, YAO Tianyue. Correlation of systemic inflammatory markers and fracture occurrence in elderly patients with osteoporosis [J]. Laboratory Medicine, 2022, 37(3): 235-239.
[9]	GU Feng, WU Yanfen, ZHAO Xinhui, HOU Zhaoyuan, WANG Zhihong, QI Hualin. Relationship between procalcitonin level and all-cause death in maintenance hemodialysis patients [J]. Laboratory Medicine, 2022, 37(2): 134-140.
[10]	YAO Hualong. Roles of PTH，CRP，OPG/PYR ratio in elderly patients with osteoporosis [J]. Laboratory Medicine, 2022, 37(12): 1146-1150.
[11]	SUN Jiaqi, JIN Weifeng, LI Ping, CHEN Shuzi, LIN Ping, LI Dan, CHEN Qing, WANG Mengxia, ZHU Yuxin. Influence of heat inactivation of blood samples at 56 ℃ for 30 min on psychiatric drug concentration monitoring [J]. Laboratory Medicine, 2022, 37(12): 1174-1177.
[12]	ZHANG Yinwang, LIU Jinyu, SONG Yunxiao, GE Wen, ZHANG Linlin, YUAN Wenhua, ZHAO Zhiyun. Relationship between preoperative SII and postoperative infection in patients with open fracture after internal fixation [J]. Laboratory Medicine, 2022, 37(11): 1071-1074.
[13]	HE Xuelian, HE Ziyi, LIU Yueyang, YU Yanzhi, ZHANG Siying. Role of line chart model based on peripheral blood-derived inflammation markers in early diagnosis of neonatal septicemia [J]. Laboratory Medicine, 2022, 37(10): 921-927.
[14]	LIU Chunxiao, YI Changlin, WANG Xiaoshan, ZHU Yongzhen, LUO Aner, CHEN Changqiang. Roles of MxA，CRP and WBC count in the differential diagnosis of acute respiratory tract viral and bacterial infections [J]. Laboratory Medicine, 2022, 37(10): 944-947.
[15]	XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55.